LICENSE, MARKETING AND DEVELOPMENT AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION, D/B/A CCT AND ALLIQUA, INC. NOVEMBER 14, 2013License, Marketing and Development Agreement • March 7th, 2014 • Celgene Corp /De/ • Pharmaceutical preparations • New York
This LICENSE, MARKETING AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of November 14, 2013 (the “Effective Date”) by and between ANTHROGENESIS CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS (“CCT”), a New Jersey corporation having a principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (“CCT”), and ALLIQUA, INC., a Florida corporation having a principal place of business at 2150 Cabot Boulevard West, Langhorne, Pennsylvania (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
LICENSE, MARKETING AND DEVELOPMENT AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION, D/B/A CCT AND ALLIQUA, INC. NOVEMBER 14, 2013License, Marketing and Development Agreement • March 24th, 2014 • Alliqua, Inc. • Surgical & medical instruments & apparatus • New York
This License, MARKETING AND DEVELOPMENT Agreement (the “Agreement”) is entered into as of November 14, 2013 (the “Effective Date”) by and between Anthrogenesis Corporation, d/b/a CELGENE CELLULAR THERAPEUTICS (“CCT”), a New Jersey corporation having a principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (“CCT”), and Alliqua, INC., a Florida corporation having a principal place of business at 2150 Cabot Boulevard West, Langhorne, Pennsylvania (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
SECOND AMENDMENT TO THE LICENSE, MARKETING AND DEVELOPMENT AGREEMENTLicense, Marketing and Development Agreement • August 6th, 2015 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus
This Second Amendment (“Second Amendment”) to the License, Marketing and Development Agreement dated November 14, 2013 (the “Original Agreement”) is effective as of April 30, 2015 (the “Second Amendment Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
FIRST AMENDMENT TO THE LICENSE, MARKETING AND DEVELOPMENT AGREEMENTLicense, Marketing and Development Agreement • November 5th, 2014 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus
This First Amendment (“First Amendment”) to the License, Marketing and Development Agreement dated November 14, 2013 (the “Agreement”) is effective as of September 26, 2014 (the “First Amendment Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (formerly Alliqua, Inc., a Florida corporation) (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
